Diabetes & Metabolism Journal (DMJ) is an international, peer-reviewed, open access, online and print journal aiming at publishing original research, reviews, and commentaries on all areas related to diabetes mellitus and metabolism. It is published bimonthly, with articles in English accepted through the process of peer review. Considering your research in related areas, we cordially invite you to submit a paper to DMJ.
Samaneh Shirkhani, Sayyed Mohammad Marandi, Mohammad Hossein Nasr-Esfahani, Seung Kyum Kim
Diabetes & Metabolism Journal 2023;47(6):771-783.
Since hepatic dysregulation contributes to the development of metabolic diseases, a therapeutic strategy to reduce liver fat accumulation is crucial for preventing type 2 diabetes. In addition to the well-known effects of exercise on decreasing diabetes rates, recent studies suggest the potential role of chlorogenic acid in preventing metabolic disorders. Thus, we examined the effects of chlorogenic acid and exercise on hepatic lipid metabolism in the setting of pre-diabetes. We found that regular exercise is an effective non-therapeutic approach for pre-diabetes, and chlorogenic acid supplementation could be an alternative to partially mimic the beneficial effects of exercise on pre-diabetes
Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon
Diabetes & Metabolism Journal 2023;47(6):796-807.
The novel SGLT-2 inhibitor, Enavogliflozin 0.3 mg, demonstrated non-inferiority in terms of efficacy and safety compared to Dapagliflozin 10 mg in Korean patients with type 2 diabetes inadequately controlled with Metformin. There were no significant differences between the Enavogliflozin and Dapagliflozin groups in terms of glycemic control, body weight, and blood pressure reduction. Additionally, Enavogliflozin exhibited a greater increase in UGCR and better HOMA-IR reduction than Dapagliflozin. The treatment was safe and well-tolerated. In summary, these results suggest that Enavogliflozin could be an attractive alternative for patients with inadequate glycemic control on Metformin alone.
Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
Diabetes & Metabolism Journal 2023;47(6):808-817.
Earlier combination therapy is an emerging strategy to provide a durable therapeutic option for patients with T2DM, and synergism with multiple pharmacological actions could address different pathophysiologies of T2DM. This study shows the 52-week clinical outcomes of a novel DPP-4 inhibitor, evogliptin, added to dapagliflozin/metformin (DAPA/MET) treatment. Evogliptin add-on therapy significantly reduced HbA1c levels by -0.65 and -0.55% compared to DAPA/MET at 24 and 52 weeks, respectively. The addition of evogliptin to DAPA/MET was a safe with no serious adverse events. The long-term triple combination of evogliptin/DAPA/MET showed superior glycaemic efficacy and tolerability in poorly controlled T2DM.
Da Young Lee, Namho Kim, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Jihee Kim, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Sung-Min Park, Nan Hee Kim
Diabetes & Metabolism Journal 2023;47(6):826-836.
To elucidate the behavioral and metabolic factors influencing continuous glucose monitoring metrics in insulin-treated individuals with type 2 diabetes mellitus (T2DM), we conducted an analysis of data collected from 122 participants in a prospective observational study. During the 10-day study period, participants consistently wore Dexcom G6 and Fitbit devices, and their dietary habits were documented. Our findings revealed that residual insulin secretion, daytime step count, HbA1c levels, and gender were the most significant factors determining effective glycemic control in insulin-treated patients with T2DM. Additionally, individuals who included snacks in their diet experienced reduced durations of hyperglycemia and glycemic variability.
Original Article- Cardiovascular Risk/Epidemiology
A substantial cardiovascular disease risk remains even after optimal statin therapy (residual cardiovascular risk). This study aimed to compare lipid parameters for predicting the first cardiovascular event among patients with T2DM receiving statin therapy, using a Korean Nationwide Cohort. Among patients achieving LDL-C <100 mg/dL, on-treatment LDL-C and non-HDL-C levels predicted MACE better than triglyceride or HDL-C levels. The predictive ability of LDL-C and non-HDL-C for MACE was prominent in patients with LDL-C ≥70 mg/dL and those at high cardiovascular risk. Our findings highlighted the importance of LDL-C and non-HDL-C, which are representative ApoB-containing lipoproteins, in cardiovascular risk assessment after statin therapy.
Jong-Ho Kim, Bong-Seoung Kim, Kyung-do Han, Hyuk-Sang Kwon
Diabetes & Metabolism Journal 2023;47(6):869-878.
Diabetes has been considered as a risk factor of shoulder adhesive capsulitis(AC). But the association between the status of diabetes and the incidence of AC has not been clearly demonstrated. In this study, a total of 3,471,745 subjects who underwent a National Health Insurance Service medical checkup in Korea between 2009 and 2010 were evaluated and were classified into the four groups according to the Type 2 diabetes(T2DM) status. And the incidence rates and hazard ratios of AC for each group were analyzed. We revealed that the risk of AC increases in prediabetic patients and is associated with T2DM status.
대한당뇨병학회는 정보통신망법 제 50조의 2, 제50조의 7 등에 의거하여,
대한당뇨병학회가 운영,관리하는 웹페이지상에서, 이메일 주소 수집 프로그램이나 그 밖의 기술적 장치 등을 이용하여 이메일 주소를 무단으로 수집하는 행위를 거부합니다.
- 게시일 2009년 7월 17일
My Page
기부
로그인
